Part 11 Is Not Going Away: The New Electronic Records Draft Guidance

Publication
Article
BioPharm InternationalBioPharm International-05-01-2003
Volume 16
Issue 5

by Wolfgang Winter, Agilent Technologies GmbH and Ludwig Huber, Agilent Technologies GmbH The rules for electronic records and signatures still remain in effect. The change means that companies must now justify their decisions on whether or not to implement specific electronic controls with documented risk assessments and considerations of the record requirements detailed in the corresponding predicate rule.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Mike Schaefers Simtra BioPharma Solutions, Shiva Khalafpour MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany
Chris Hagan, SCIEX
Daniel Fischer, Tevard
Junevity Co-founder & CEO, John Hoekman, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.